- Home
- ENTX vs GNLX Comparison
ENTX vs GNLX Comparison
Compare ENTX & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTX
- GNLX
- Stock Information
- Founded
- ENTX 2010
- GNLX 2001
- Country
- ENTX Israel
- GNLX United States
- Employees
- ENTX N/A
- GNLX N/A
- Industry
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- ENTX Health Care
- GNLX Health Care
- Exchange
- ENTX Nasdaq
- GNLX Nasdaq
- Market Cap
- ENTX 90.2M
- GNLX 85.0M
- IPO Year
- ENTX 2018
- GNLX 2023
- Fundamental
- Price
- ENTX $2.30
- GNLX $3.86
- Analyst Decision
- ENTX Strong Buy
- GNLX Strong Buy
- Analyst Count
- ENTX 1
- GNLX 4
- Target Price
- ENTX $10.00
- GNLX $18.25
- AVG Volume (30 Days)
- ENTX 83.9K
- GNLX 288.1K
- Earning Date
- ENTX 03-07-2025
- GNLX 03-31-2025
- Dividend Yield
- ENTX N/A
- GNLX N/A
- EPS Growth
- ENTX N/A
- GNLX N/A
- EPS
- ENTX N/A
- GNLX N/A
- Revenue
- ENTX $99,000.00
- GNLX $8,000.00
- Revenue This Year
- ENTX N/A
- GNLX N/A
- Revenue Next Year
- ENTX N/A
- GNLX N/A
- P/E Ratio
- ENTX N/A
- GNLX N/A
- Revenue Growth
- ENTX 607.14
- GNLX N/A
- 52 Week Low
- ENTX $0.68
- GNLX $1.60
- 52 Week High
- ENTX $3.35
- GNLX $9.82
- Technical
- Relative Strength Index (RSI)
- ENTX 40.07
- GNLX 59.89
- Support Level
- ENTX $2.22
- GNLX $3.03
- Resistance Level
- ENTX $2.46
- GNLX $4.23
- Average True Range (ATR)
- ENTX 0.18
- GNLX 0.48
- MACD
- ENTX -0.05
- GNLX 0.09
- Stochastic Oscillator
- ENTX 16.07
- GNLX 51.47
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.